Purpose Preclinical studies in rats showed that two of 99m Tc(CO) 3 (ASMA) isomers (rac-and L-ASMA) had pharmacokinetic properties equivalent to that of 131 I-OIH, the radiopharmaceutical standard for the measurement of effective renal plasma flow. The aim of this study was to evaluate the pharmacokinetics of 99m Tc(CO) 3 (ASMA) isomers in healthy human subjects. I-OIH into healthy human subjects followed by sequential imaging, plasma clearance measurements and timed urine collection. Plasma protein binding, red cell uptake and percent injected dose in the urine were determined. Urine from each group of volunteers was analyzed for metabolites by HPLC. Results Image quality was excellent with all three agents. Each 99m Tc(CO) 3 (ASMA) preparation was excreted unchanged in the urine. The plasma clearance ratio ( I-OIH clearance ratio (∼50-60 %). Red cell uptake was similar for all three tracers (6-9 %), and all tracers had a relatively rapid renal excretion; at 3 h, the 
I-OIH, the radiopharmaceutical standard for the measurement of effective renal plasma flow. The aim of this study was to evaluate the pharmacokinetics of 99m Tc(CO) 3 (ASMA) isomers in healthy human subjects. Methods Three ASMA ligands (rac-, L-and D-ASMA) were labeled with 99m Tc(CO) 3 using an IsoLink kit (Covidien), and each formed 99m Tc(CO) 3 (ASMA) tracer was co-injected with 131 I-OIH into healthy human subjects followed by sequential imaging, plasma clearance measurements and timed urine collection. Plasma protein binding, red cell uptake and percent injected dose in the urine were determined. Urine from each group of volunteers was analyzed for metabolites by HPLC. Results Image quality was excellent with all three agents. Each 99m Tc(CO) 3 (ASMA) preparation was excreted unchanged in the urine. The plasma clearance ratio ( 99m Tc(CO) 3 (ASMA)/ 131 I-OIH) was 81±3 % for D-ASMA compared to only 20±4 % for L-ASMA and 37±7 % for rac-ASMA; the 81 % clearance ratio for D-ASMA isomer is still∼ 30 % higher than the 99m Tc-MAG3/ 131 I-OIH clearance ratio (∼50-60 %). Red cell uptake was similar for all three tracers (6-9 %), and all tracers had a relatively rapid renal excretion; at 3 h, the 
Introduction
Renal radionuclide studies can provide a simple, noninvasive method of evaluating kidney function and can assist in the early detection and diagnosis of chronic kidney disease. In view of superior physical characteristics of 99m Tc over 131 I with regards to γ-camera imaging and radiation dose to the patients, multiple 99m Tc renal tracers have been evaluated as potential alternatives to 131 I-o-iodohippurate ( 131 I-OIH), which has been recognized as the radiopharmaceutical standard for the measurement of effective renal plasma flow (ERPF).
To date, the most widely used alternative to 131 I-OIH is 99m Tc-mercaptoacetytriglycine ( 99m Tc-MAG3), but its success is largely due to excellent scintigraphic imaging qualities and not an improvement in renal clearance, which is still o n l y ∼ 5 0 -6 0 % t h a t o f 1 I-OIH [6] . In addition, a small percentage of 99m Tc-MAG3 and 99m Tc-LL-EC is eliminated via the hepatobiliary pathway, which can lead to problems in image interpretation, particularly in patients with renal failure [7] [8] [9] [10] [11] . Morover, the continuing effort to develop a 99m Tc renal pharmaceutical with both reduced hepatobiliary excretion and superior pharmacokinetic properties has been simulated by a report noting marked variability of 99m Tc-MAG3 clearance compared to para-aminohippuran (PAH), the non-radioactive gold standard for the measurement of ERPF [12] , as well as the studies concluding that the 99m Tc-MAG3 clearance is not accurate enough to evaluate a change in kidney function [13] [14] [15] .
Further attempts to search for a better renal tubular agent led to the synthesis of 9 Tc-tricarbonyl core evaluated in humans [16] . Although the image quality was excellent with this agent and 99m Tc(CO) 3 (LAN) had a relatively rapid renal excretion, its plasma clearance was substantially lower than the plasma clearance of 131 I-OIH [16] . Recently, we showed that a new r e n a l t r a c e r 9 9 m Tc ( C O ) 3 
-n i t r i l o t r i a c e t i c a c i d [ 99m
Tc(CO) 3 (NTA)] not only gave kidney images of superb quality, but also showed identical pharmacokinetic properties to those of 131 I-OIH based on studies in rats, normal humans and patients with chronic kidney disease [17] [18] [19] .
In a continuation of our efforts to develop renal tubular tracers with a clearance equivalent to that of PAH, which has a clearance 10- 
Materials and Methods

General
The ASMA ligand was synthesized as previously described as a racemic mixture of D-and L-isomers (rac-ASMA) [21, 22] and as the enantiomerically pure L-and D-isomers (L-ASMA and D-ASMA, respectively) [23] . I-OIH was prepared as previously described by the isotope exchange reaction between non-radioactive hippuran (OIH) and radioactive sodium iodide (Na 131 I) [17] . Analysis of the radiolabeled compounds was performed on a high-performance liquid chromatography (HPLC) instrument (Beckman System Gold Nouveau) equipped with a Beckman model 170 radiometric detector, a model 166 ultraviolet-visible light detector, and a Beckman C18 RP Ultrasphere octyldecyl silane column (5-μm, 4.6 × 250 mm). The solvent system was 0.05 M triethylammonium phosphate (TEAP) buffer pH 2.5 (solvent A) and ethanol (solvent B), and the flow rate was 1 ml/min. The gradient method used was the same as reported previously [24] . The same HPLC system and conditions were used for purification and analysis of 99m Tc tracers and for the urine Tc(CO) 3 (ASMA) complexes; asterisk denotes asymmetric carbon, and ellipse encloses dangling the carboxylate group metabolite studies. Urine, plasma and red blood cell radioactivity were measured with an automated 2480 Wizard 2 gamma counter (Perkin-Elmer) with a 3-inch NaI(Tl) detector.
Radiosynthesis of 99m
Tc(CO) 3 (ASMA)
All three ASMA ligands (rac-, L-and D-ASMA) were labeled according to the previously described procedure [20] 3 ] + (0.5 ml, ∼2 GBq/ml) and an aqueous solution of the corresponding ASMA ligand (0.2 ml, 1 mg/ml) were combined in a sealed vial, and the pH was adjusted to∼7 with 1 M NaOH. After heating for 30 min at 70 ºC, the vial was cooled to room temperature. 99m Tc(CO) 3 (ASMA) was purified by HPLC as described above, and the radiochemical purity was>98 %. The two diastereomers of 99m Tc(CO) 3 (ASMA) formed during the labeling process for each L-and D-ASMA ligand could not be separated by HPLC, and the tracer was collected in a single fraction and further evaluated as a mixture of products. Ethanol was partially removed by N 2 gas. The collected 99m Tc(CO) 3 (ASMA) fraction was subsequently diluted in phosphate-buffered saline (PBS) by a factor of 20 to ensure that any remaining organic solvent comprised less than 5 % of the solution (v/v). The HPLC-purified product was sterilized by filtration (sterile filter Millex-GS, 22 μm, Millipore), and the final concentration was 37 MBq/ml. After formulation, the identity and the chemical and radiochemical purities of the 99m Tc(CO) 3 (ASMA) tracer were checked using HPLC and Re(CO) 3 (ASMA) as a nonradioactive standard [25] . The bubble point test of the sterilization filter was performed before the injection of 99m Tc(CO) 3 (ASMA). Each final preparation (pH 7.4) was tested and determined to be sterile and pyrogen free.
Healthy Volunteer Studies
All studies were performed with the approval of the Emory University Institutional Review Board and conducted under the auspices of IND 112,322 from the US Food and Drug Administration. Written informed consent was obtained from each volunteer. Nine healthy volunteers (4 male, 5 females; mean age±SD, 28±7 years; range 18-40 years) participated in this study and were divided randomly into three groups of three subjects each. Enrolled participants had no history of kidney or bladder diseases, and pregnancy was excluded in female volunteers using a urine pregnancy test. Each volunteer was asked to drink a glass of water before the study. In addition, safety assessments for each volunteer included the measurement of vital signs at pre-injection baseline and after imaging. Also, clinical laboratory tests were performed at preand post-injection and included complete blood count, standard chemistry panel and urinalysis.
Imaging was performed using an Infinia camera (GE Healtcare) with 3/8-inch crystal and a high-energy collimator after each volunteer had been coinjected with 9 9 m Tc ( C O ) 3 ( A S M A ) ( ∼ 7 4 M B q ) a n d 1 3 1 I -O I H (∼ 9.25 MBq). Each subject was imaged supine with the kidneys and bladder within the field of view. At the conclusion of the 24-min acquisition, a postvoid image of the kidneys was obtained as well as an anterior image over the gallbladder and abdomen. Data were acquired and processed on a Xeleris computer (GE Healthcare) with an extensive in-house upgrade of the original QuantEM renal software (GE Healthcare). Renogram curves were generated using cortical (parenchymal) and whole-kidney regions of interest (ROIs), and the time-to-peak height (TTP) and 20-min-to-maximum count ratios (20 min/max) were calculated. Plasma clearances for 99m Tc(CO) 3 (ASMA) and 131 I-OIH were determined using the single injection, two-compartment model of Sapirstein et al. [26] after ten venous blood samples had been obtained at 3, 5, 10, 20, 30, 45, 60, 90, 120 and 180 min post-injection. The value of plasma clearance (Cl) was normalized for body surface area (BSA), which was calculated by means of the Haycock formula [27] , and expressed in ml/min/1.73 m 2 (Cl/ BSA).
The volunteers voided at 30, 90 and 180 min post-injection to determine the percent dose in the urine. Plasma protein binding (PPB) and the percent uptake in the erythrocytes (RBC) were determined as described previously [18] in duplicate, and the mean values were reported. No correction was made for plasma trapped in the red blood cell sample.
In vivo stability and metabolism of the complex were determined by comparing the HPLC analysis of a 30-min urine sample for each 99m Tc(CO) 3 (ASMA) preparation with that of the purified complex.
Statistical Analysis
Statistical analyses were performed using a two-tailed Student's t test. A P-value of<0.05 was considered statistically significant. All results are expressed as the mean±SD.
Results
The ASMA ligand was effectively radiolabeled with the [ 99m Tc(CO) 3 Tc-tricarbonyl core and with high radiochemical purity of>98 % [20] . In all complexes, the ASMA ligand coordinated tridentately and facially to form a 99m Tc(CO) 3 (ONO) coordination sphere, leaving one carboxyl group uncoordinated (Fig. 1) Tc(CO) 3 (rac-ASMA), are obtained as a mixture of diastereomers because of the chirality of the ASMA ligand [25] . The 99m Tc tracers are very hydrophilic and dianionic at physiological pH since the dangling carboxylate group is deprotonated at that condition.
In our human studies, each (Table 1 ).
An aliquot from the 30 min urine sample from each group of volunteers was analyzed by HPLC to determine whether Image quality was excellent with all three 99m Tc agents. A representative study for each tracer is presented in Fig. 3 . There was no significant difference in relative uptake in the left and right kidneys for all three Tc tracers (0.39±0.13 for L-ASMA and 0.30±0.18 for rac-ASMA). For comparison, the normal value for whole kidney 20 min/max ratio for 99m Tc-MAG3 was 0.24± 0.14 based on an earlier study of 106 subjects referred for potential kidney donation [3] . Since the 131 I-OIH renogram curves were quite noisy because of the relatively low counting rate resulting from the lower administered dose, poor capture of 364-keV photon of 131 I by 9.5 mm crystal and the fact that the high-energy collimator is not optimized for 364-keV photons, it was not possible to calculate reliable TTP and 20 min/max for 131 I-OIH. Finally, none of the subjects had activity identified in the gall bladder or intestines on the anterior images obtained at 30 min over the gall bladder and abdomen.
Discussion
The chemical structure of the radiolabeled chelate must be known to determine the lipophilicity, geometric shape, net charge and charge distribution of the agents since these properties have a major influence on protein binding, renal specificity, rate of excretion and in vivo distribution. The ASMA ligand used in our studies for preparation of 99m Tc-tricarbonyl radiotracers is a geometrical isomer of the nitrilotriacetic acid (NTA) ligand. Based on the structural similarity of 99m Tc(CO) 3 (ASMA) and 99m Tc(CO) 3 (NTA) (Fig. 1) , we anticipated a comparable renal handling of those two isomers. These tracers have very similar properties at physiological pH.
They are both very hydrophilic due to an overall dianionic charge resulting from an identical ONO coordination mode of the ligands to the [ 99m Tc(CO) 3 ] + core and the presence of a deprotonated dangling carboxylate group. However, in contrast to a symmetrical NTA ligand that forms a single complex upon coordination to the 99m Tc tricarbonyl core with a wellestablished structure based on the characterization of its Re analog [17] , the ASMA ligand with the asymmetric carbon produces a mixture of diastereomers, which differ only in the position and orientation of the uncoordinated carboxylate group on the aspartate chelate ring (endo when the dangling group projects toward the face defined by the carbonyl ligands or exo when projecting away from the tricarbonyl face; please see the cited references for a full depiction of diastereomers) [25, 20] . Brifly, since endo-and exo- Tc(CO) 3 (rac-ASMA) tracer is also identical to the chromatograms of D-ASMA and L-ASMA radiotracers (Fig. 2) . Nevertheless, even with differences in their structural features, and the fact that I-OIH including high specificity for renal excretion. Also, they both had less hepatic and intestinal activity than 131 I-OIH in an animal model of renal failure [17, 20] . Since there are interspecies differences and the pharmacokinetics of renal tracers in humans does not perfectly mirror those obtained in rats, evaluation of 99m Tc(CO) 3 (ASMA) isomers in humans was warranted.
Our present studies in healthy volunteers showed differe n c e s n o t o n l y i n t h e p h a r m a c o k i n e t i c s o f 99m Tc(CO) 3 Tc(CO) 3 (ASMA) preparations (Fig. 3) . Second, the best I-OIH clearance ratio (Fig. 4) [2, 28, 29] , although it is still inferior to the 100 % (Table 1) ; it is similar to that of 99m Tc(CO) 3 (NTA) (PPB, 43 %), but it is much lower than that of 99m Tc-MAG3 (PPB, ∼80 %). As a result of lower protein binding, a renal tracer can be eliminated by glomerular filtration in addition to tubular extraction [30] . Because the clearance of I-OIH at 10 min [20] exceeded the expected 40 % filtration fraction in rats [31] .
Since we have demonstrated that 99m Tc(CO) 3 (D-ASMA) has a higher clearance and rate of urine excretion than 99m Tc(CO) 3 (L-ASMA) and 99m Tc(CO) 3 (rac-ASMA) in humans, it can be assumed that it fits more efficiently to the renal transport proteins and that the chelate ring stereochemistry plays an important role in renal handling . It has been previously shown that the pharmacokinetic properties of renal tracers are susceptible to the presence of functional groups, chelate ring stereochemistry of the ligand and positional isomerism of the functional group. For example, one of the isomers of an early 9 9 m Tc renal tracer, syn-9 9 m Tc-N,N'-bis-(mercaptoacetyl)-2,3-diaminopropionic acid (syn99m Tc-CO 2 -DADS), is excreted faster than the anti-isomer in normal subjects [32, 15, 33] . Similar to our findings, pharmacokinetic properties in rats were almost identical for all separated 99 Tc-EC isomers, but in humans, the clearance of 99 Tc-DD-EC was significantly higher than the clearance of 99m Tc-DL-EC [6] . Other studies reported that syn- Tc-D-MAEC) had a higher clearance in humans than its L-MAEC isomer [34] . It was also shown that the efficiency of renal handling of the derivatives of 99m Tc-MAG3 was influenced to a great extent by the configuration of isomers and the site of substitution [35] [36] [37] .
Conclusions
Image quality was uniformly excellent for all three 99m Tc(CO) 3 (ASMA) preparations. Preliminary data in humans suggest that the pharmacokinetic properties of 99m Tc(CO) 3 (D-ASMA) are superior to those of the other ASMA isomers and also superior to those of The development of radiopharmaceuticals for clinical application in humans is critically dependent on evaluation and testing in animal models. However, the results of this study are a testament to the fact that subtle yet significant differences may exist between tracer pharmacokinetics in animal models and in humans and emphasize that the animal model can only serve as a guide and not a replacement for human testing. 
